Trevi Therapeutics, Inc.
NASDAQ:TRVI
4 (USD) • At close December 24, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Trevi Therapeutics, Inc. |
Symbool | TRVI |
Munteenheid | USD |
Prijs | 4 |
Beurswaarde | 357,462,800 |
Dividendpercentage | 0% |
52-weken bereik | 1.27 - 4.675 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Ms. Jennifer L. Good |
Website | https://www.trevitherapeutics.com |
An error occurred while fetching data.
Over Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)